SCHEMBL4876349

SCHEMBL4876349

COc1cccc([C@]2(C(=O)O)CC[C@H](NC(c3ccccc3)c3ccccc3)CC2)c1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.46
OPRD1 P41143 1/20 0.46
OPRK1 P41145 1/20 0.46
OPRL1 P41146 1/20 0.46
KMT2A Q03164 4/20 0.45
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 3/20 0.45
MAPK1 P28482 1/20 0.45
MGLL Q99685 1/20 0.44
ALOX15 P16050 1/20 0.44
NPY1R P25929 1/20 0.43
GRIN2B Q13224 3/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4877603 1.00 OPRM1 (0.46) OPRM1OPRD1OPRK1OPRL1KMT2A
SCHEMBL4876357 1.00 OPRM1 (0.46) OPRM1OPRD1OPRK1OPRL1KMT2A
SCHEMBL4881637 0.92 OPRD1 (0.45) OPRM1OPRD1OPRK1OPRL1KMT2A
SCHEMBL4873596 0.92 OPRD1 (0.45) OPRM1OPRD1OPRK1OPRL1KMT2A
SCHEMBL4873590 0.92 OPRD1 (0.45) OPRM1OPRD1OPRK1OPRL1KMT2A
SCHEMBL4878461 0.82 OPRM1 (0.46) OPRM1OPRD1OPRK1OPRL1KMT2A
SCHEMBL4878471 0.82 OPRM1 (0.46) OPRM1OPRD1OPRK1OPRL1KMT2A
SCHEMBL4872040 0.82 ALDH1A1 (0.51) KMT2AALDH1A1MEN1MAPT
SCHEMBL4872031 0.82 ALDH1A1 (0.51) KMT2AALDH1A1MEN1MAPT
SCHEMBL5772883 0.81 OPRM1 (0.44) OPRM1OPRD1OPRK1OPRL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096922-A1 Novel Sulfonamide derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-04-24 US disclosed
EP-1736467-A1 NOVEL SULFONAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096922-A1 Novel Sulfonamide derivative NR4A1, NR4A2, NR4A3 OPRM1 1290/4885OPRD1 628/4885OPRK1 2515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.